

# Chemotherapy of Cancer

CARTER/BAKOWSKI/HELLMANN

# CHEMOTHERAPY OF CANCER

STEPHEN K. CARTER, MD,

Director of Northern California Cancer Program;  
Formerly, Deputy Director of Division of Cancer  
Treatment, National Cancer Institute, U.S.A.

MARIE T. BAKOWSKI, BSc, MB, MRCP,

Research Fellow, Imperial Cancer Research Fund  
Department of Medical Oncology,  
St. Bartholomew's Hospital, London, England

KURT HELLMANN, DM, DPhil,

Honorary Consultant to the Westminster Hospital,  
and Head of Cancer Chemotherapy Department,  
Imperial Cancer Research Fund,  
London, England

A Wiley Medical Publication

JOHN WILEY & SONS

New York • London • Sydney • Toronto

## CAUTION

The indications for and dosages of drugs and their combinations in this book have been taken from the world medical literature. The potential user of any of these drugs or regimes should however consult the original literature or see package inserts for use and dosage. Furthermore, the medications described do not necessarily have the specific approval of the Food and Drug Administration or any other countries' drug regulatory authority for use in the diseases and dosages for which they are recommended.

Because standards for usage change, it is advisable to keep abreast of revised recommendations, particularly those concerning new drugs.

Copyright © 1977 by John Wiley & Sons, Inc.

All rights reserved. Published simultaneously in Canada.

No part of this book may be reproduced by any means, nor transmitted, nor translated into a machine language without the written permission of the publisher.

### **Library of Congress Cataloging in Publication Data:**

Carter, Stephen K  
Chemotherapy of cancer.

(A Wiley medical publication)  
Includes index.

1. Cancer - Chemotherapy. 2. Antineoplastic agents.  
I. Bakowski, Marie T., joint author. II. Hellmann,  
Kurt, joint author. III. Title. [DNLM: 1. Neoplasms  
\* Drug therapy. 2. Antineoplastic agents. QZ67C325c]  
RC271.C5C327 616.9'94'061 77-8142  
ISBN 0-471-02935-1

Printed in the United States of America

10 9 8 7 6 5 4 3 2

# CONTENTS

## SECTION I - INTRODUCTION

### CHAPTER 1. THE STRATEGY OF CANCER TREATMENT

Treatment Modalities	3
Combined Modality Approach	4

### CHAPTER 2. BASIC CONCEPTS IN CANCER CHEMOTHERAPY

Introduction	9
Cell Kill Hypothesis	10
Cell Kinetics	11
Pharmacokinetics	13
Drug Dosage and Schedule	15
Combination Chemotherapy	16

### CHAPTER 3. CLINICAL TRIALS IN CANCER CHEMOTHERAPY

Introduction	21
Protocol Design	21
Phase I Trials	23
Phase II Trials	25
Phase III Trials	31

## SECTION II - ANTICANCER DRUGS

### CHAPTER 4. ANTICANCER DRUGS

Introduction	39
Drug Administration	39
Drug Toxicity	43
Mechanisms of Action	43
Alkylating Agents	
Mechlorethamine	45
Busulfan	46
Chlorambucil	47
Cyclophosphamide	48
Melphalan	49
Thiotepa	50

Antimetabolites	
Methotrexate	51
6-Mercaptopurine	53
Thioguanine	54
5-Fluorouracil	55
Ftorafur	56
Cytosine arabinoside	57
5-Azacytidine	58
Plant Alkaloids	
Vinblastine	59
Vincristine	60
VM 26	61
VP 16	62
Antitumor Antibiotics	
Actinomycin D	63
Adriamycin	64
Bleomycin	66
Daunorubicin	67
Mithramycin	68
Mitomycin C	69
Nitrosoureas	
Carmustine	70
Lomustine	71
Semustine	72
Streptozotocin	73
Enzymes and Random Synthetics	
L-asparaginase	74
Cis-platinum diammine dichloride	75
Dacarbazine	76
Dibromomannitol	77
Hexamethylmelamine	77
Hydroxyurea	78
Mitotane	79
Procarbazine	80
Razoxane	82
Adrenocorticosteroids	
Prednisone and Prednisolone	83
Dexamethasone	84

Androgens	
Calusterone	85
Dromostanolone propionate	85
Fluoxymesterone	86
Nandrolone phenylpropionate	86
Testolactone	87
Testosterone propionate	87
Estrogens and Antiestrogens	
Diethylstilbestrol	88
Ethinyl estradiol	89
Fosfestrol	89
Nafoxidine	90
Tamoxifen	90
Progestogens	
Hydroxyprogesterone caproate	91
Medroxyprogesterone caproate	91
Megestrol acetate	92
Norethindrone acetate	92
Miscellaneous	
Estramustine phosphate	93

### SECTION III - CHEMOTHERAPY OF CANCER

#### CHAPTER 5

Introduction	97
Part 1. Solid Tumors	
Dermatologic Cancer	
Dermatologic cancer (excluding melanoma)	100
Malignant melanoma	103
Endocrinologic Cancer	
Adrenocortical carcinoma	107
Islet cell carcinoma	109
Malignant carcinoid	112
Thyroid carcinoma	114
Gastrointestinal Cancer	
Colorectal adenocarcinoma	116
Esophageal carcinoma	123
Gastric adenocarcinoma	125
Hepatoma	131
Pancreatic adenocarcinoma	134

Gynecologic Cancer	
Breast carcinoma	138
Cervical carcinoma	149
Choriocarcinoma	152
Endometrial carcinoma	156
Ovarian carcinoma	161
Urologic Cancer	
Bladder carcinoma	169
Prostatic carcinoma	174
Renal cell carcinoma	178
Testicular carcinoma	181
Miscellaneous Solid Tumors	
Adult soft tissue sarcomas	189
Bronchogenic carcinoma	193
Glioblastoma multiforme	200
Squamous cell carcinoma of head and neck	205
Part 2. Pediatric Solid Tumors	
Embryonal rhabdomyosarcoma	212
Ewing's sarcoma	216
Medulloblastoma	218
Neuroblastoma	221
Osteogenic sarcoma	225
Wilms' tumor	229
Part 3. Hematologic Malignancies	
Acute lymphocytic leukemia	234
Acute myelogenous leukemia	242
Chronic lymphocytic leukemia	248
Chronic myelogenous leukemia	250
Hodgkin's disease	253
Non-Hodgkin's lymphomas	261
Multiple myeloma	270
Polycythemia vera	274

## SECTION IV - NEW APPROACHES

### CHAPTER 6. COMBINED MODALITY THERAPY

Introduction	279
Adult Solid Tumors	
Breast carcinoma	282
Bronchogenic carcinoma	284
Colorectal adenocarcinoma	285
Gastric adenocarcinoma	285
Pancreatic adenocarcinoma	286
Cervical carcinoma	287
Endometrial carcinoma	288
Ovarian carcinoma	289
Other adult solid tumors	290
Pediatric Solid Tumors	
Embryonal rhabdomyosarcoma	290
Ewing's sarcoma	291
Osteogenic sarcoma	292
Wilms' tumor	294
Discussion	295

### CHAPTER 7. IMMUNOTHERAPY

Introduction	301
Immunotherapeutic Approaches	302
Malignant melanoma	302
Acute leukemias	304

### CHAPTER 8. NEW DRUGS

Drug Development	309
New Drugs	313
Iphosphamide	313
Galactitol	314
Asaley	314
Baker's antifol	315
Cyclocytidine	316
Diglycoaldehyde	317
Chromomycin A <sub>3</sub>	317
Piperazinedione	319
Cytembena	320
Conclusion	321



APPENDIX A. SOURCES OF F.D.A. APPROVED DRUGS	325
APPENDIX B. DRUG TOXICITY	327
APPENDIX C. DRUG-TUMOR INTERACTIONS	331
INDEX	338

SECTION I

---

# INTRODUCTION



## CHAPTER 1

# THE STRATEGY OF CANCER TREATMENT

### Treatment Modalities

In the treatment of cancer one of the basic assumptions is that all malignant cells should be destroyed, removed or neutralized to achieve cure. Whether successful treatment has to eradicate all neoplastic cells or bring the cell number down to a level that can be controlled by the host's supposed immunologic defenses against the tumor is unknown at present. Five therapy modalities exist today which can be used in an attempt to bring about the requisite malignant cellular reduction: surgery, radiotherapy, endocrinotherapy, chemotherapy and immunotherapy.

As has often been stated, cancer is not one but a hundred different diseases each with its own natural history of spread, responsiveness to and failure pattern after various therapeutic maneuvers. For some tumors, a specific therapeutic procedure may represent the clear cut choice, while for others, a number of satisfactory alternatives may exist. This is true for most tumors and therefore optimal therapy is determined not only by the nature and extent of the disease, but also by the experience of the oncologists responsible for the patient's care and the facilities available for treatment.

Cancer can be classified into two major categories: solid tumors and hematologic malignancies. Solid tumors are initially confined to specific tissue or organ sites. In time, however, cancer cells break off from the original tumor mass, enter the blood or lymph system, reach distant parts of the body, and start secondary growths there (metastasis). When this occurs, the disease is in the disseminated stage. Conversely, hematologic malignancies involve the blood and lymph systems, and for this reason, they are frequently disseminated diseases from the very beginning.

In solid tumors, surgery and/or radiotherapy are the traditional, primarily chosen treatments. Neither modality, however, can be considered curative once disease has metastasized beyond the local

## The Strategy of Cancer Treatment

region (primary site and nearby lymph nodes) or has involved a vital organ extensively. Chemotherapy is relegated almost exclusively to secondary or tertiary treatment of solid tumors, i.e. when surgery and radiotherapy fail. Conversely, in hematologic malignancies, chemotherapy is the treatment of choice at diagnosis.

There are many approaches to treating a patient with cancer. Cancer is not a single disease but a multiplicity of diseases with variation being dependent on the organ system involved. Each type of cancer has its own diagnostic problems and its potential responsiveness to a wide range of therapeutic interventions. Each disease requires its own therapeutic strategy which is a unique blend of the various modalities available for usage. The development of this strategy requires a multidisciplinary input from surgical oncologists, radiation oncologists, medical oncologists and pathologists. For any given stage, of any given tumor type, the surgical oncologist offers the potential of more or less radical procedures. The radiation oncologist offers a range of new fractionation schedules and new delivery systems. The chemotherapist offers an endless mix of new drugs and drug combinations, while the immunologist offers a wide range of approaches to immune modulation. Clearly some priorities need to be set especially when one considers the unlimited numbers of interactions which can occur with combined modality studies. The priorities which have to be set should ideally be worked out within a disease-oriented strategy which takes into consideration the exigencies of the natural history of the disease under various classical therapeutic maneuvers.

### Combined Modality Approach

One of the most important developments in the strategy of cancer treatment has been the full appreciation of the combined modality approach in adult solid tumor therapy (1). The pediatric oncologist has known for a long time the value of a multimodal therapeutic attack because of the results achieved in Wilms' tumor (2,3,4), embryonal rhabdomyosarcoma (5,6,7) and Ewing's sarcoma (8,9). This potential is now being appreciated by the clinical oncologist treating breast cancer (10,11) and other major cancer killers (12,13,14).

Experimentally, the control of tumors requires eradication of the last neoplastic cell (15). Clinically it has been obvious for many years that surgical removal or radiotherapeutic ablation of

## Combined Modality Approach

"localised" masses has not achieved the desired cancer control in a large number of patients. Oncologists have come to realize that many tumors which are apparently localized are in fact microscopically disseminated. We do not have the diagnostic tools to diagnose this, but recurrence proves that microscopic dissemination has taken place. Intensive study of the "natural history" of relapses after surgical or radiotherapeutic curative intent approaches has indicated groups in whom dissemination can be assumed to have occurred at the time of diagnosis in a large percentage of cases. Such groups include breast cancer patients with positive axillary lymph nodes, large bowel cancer cases with disease penetrating through the entire bowel and/or involving the regional lymph nodes, and all curative resection gastric cancer, pancreatic cancer and lung cancer patients.

If disseminated disease exists at the time of diagnosis then some therapeutic approach is needed which has the ability to control tumor cells anywhere in the body. Chemotherapy is at this time the master candidate for adjuvant usage to local therapy because of its proven cell kill potential in a wide range of human malignancies. As with surgery or radiotherapy, chemotherapy can be curative or palliative in varying degrees depending upon the individual tumor. By "cure" is meant that the life expectancy of the treated cancer patient is the same as "normal" life expectancy. Specifically, the same as that of a matched cohort in the general population. "Cures" from drugs alone have been obtained in such diseases as acute lymphocytic leukemia, Hodgkin's disease, diffuse histiocytic lymphomas, testicular cancer, choriocarcinoma and Burkitt's tumor (16). Chemotherapy achieves a high rate of objective tumor regression and enhanced survival in acute myelocytic leukemia, non-Hodgkin's lymphomas, multiple myeloma, adenocarcinomas of the breast and ovary and the chronic leukemias.

It has long been known experimentally that chemotherapy is more effective when tumor masses are small than when the tumor cell burden is high. The concept of first order kinetic cell kill by drugs (fixed percentage kill rather than fixed number kill per effective dose) means that, with a small tumor burden, total cell kill can be achieved with a reasonable number of repetitive doses which with a large tumor cell burden would still leave residual cells which would eventually develop "resistance" and start to grow again. The assumption underlying the adjuvant chemotherapy trials of today is

## The Strategy of Cancer Treatment

that the drug regimens which can give objective regressions (greater than 50% shrinkage of measurable tumor mass) in advanced diseases will be able to achieve total cell kill when applied to the microscopic residual disease remaining after surgical removal of the great mass of tumor bulk. The possibility that this assumption may be valid is borne out by the preliminary results of Fisher and Bonadonna (10,11) in breast cancer and the results of Jaffe and Cortes (17,18) in osteogenic sarcoma.

The utilization of immunotherapy as an adjuvant to surgery and/or radiotherapy rests on many of the same assumptions outlined for chemotherapy. The critical differences between immunotherapy and chemotherapy at this point in time within the framework of this strategy are as follows: (a) Immunotherapy is postulated to kill tumor cells by zero order kinetics (fixed number); (b) immunotherapy is postulated to be able to control only small cell numbers, therefore, (c) regression of advanced disease cannot be utilized as a predictor for adjuvant choice; (d) the correlation of tests, which measure immune response enhancement with immune modulation, and tumor cell control is still not established; (e) the question of disease specificity with various tools for immune modulation remains to be established.

As we attempt to develop our therapeutic strategies the importance of adequately staging all patients is easily evident. We need to strive for total international agreement on staging approaches and staging nomenclatures so that we can correlate the massive data which are being reported each year. We need to approach each tumor with clinical staging initially and pathologic staging wherever possible. The conflicts between clinical and pathologic staging systems need to be resolved recognizing that each tumor will have to be staged with an individualized mix of clinical and pathologic technique as available within the location patterns of spread for each type.

We are in an exciting period of therapeutic research in which the potential to increase the control rate of major tumor types is high. If we are to fulfill this potential we will need to develop even more fully the multidisciplinary input to disease-oriented strategy. No longer can any therapeutic modality isolate itself and claim certain tumors and stages for their own. Multimodal cooperation will be the routine of the future.

## The Strategy of Cancer Treatment

### References

1. Carter SK, Soper WT: Integration of chemotherapy into combined modality treatment of solid tumors. 1. The overall strategy. Cancer Treatment Reviews 1: 1-13, 1974.
2. Sullivan MP, Sutow WW: Successful therapy for Wilms' tumor. Texas Med 65: 46-51, 1969.
3. Sutow WW, Gehan EA, Heyn RM et al: Comparison of survival curves 1956 versus 1962 in children with Wilms' tumor and neuroblastoma. Pediatrics 45: 800-811, 1970.
4. Farber S: Chemotherapy in the treatment of leukemia and Wilms' tumor. JAMA 198: 826-836, 1966.
5. Pinkel D, Pratt C: Embryonal rhabdomyosarcoma. In, Holland J, Frei E (eds): Cancer Medicine, Philadelphia, Lea and Febiger, 1973, pp. 1900-1907.
6. Pratt CB, Hustu HO, Fleming IP et al: Coordinated treatment of childhood rhabdomyosarcoma with surgery, radiotherapy and combination chemotherapy. Cancer Res 32: 606-610, 1972.
7. Wilbur J, Sutow W, Sullivan M, et al: Successful treatment of rhabdomyosarcoma with combination chemotherapy and radiotherapy (abstr.). Proceedings American Society of Clinical Oncology, Inc, Chicago, 1971.
8. Hustu HO, Holton C, James P et al: Treatment of Ewing's sarcoma with concurrent radiotherapy and chemotherapy. J Pediatrics 73: 249-251, 1968.
9. Johnson RE, Pomeroy TC: Integrated therapy for Ewing's sarcoma. Am J Roentgenol 114: 532-535, 1972.
10. Fisher B, Carbone P, Economou S, et al: L-Phenylalanine mustard (L-PAM) in the management of primary breast cancer - A report of early findings. New Engl J Med 292: 117-122, 1975.
11. Bonadonna G, Brusamolino E, Valagussa P et al: Adjuvant study with combination chemotherapy in operable breast cancer. Proc Am Assoc Cancer Res 16: 254, 1975 (abstr.).



## The Strategy of Cancer Treatment

12. Carter SK: Large bowel cancer - The current status of treatment  
J Natl Cancer Inst 56: 3-10, 1976.
13. Comis RL, Carter SK: Integration of chemotherapy into a combined modality treatment of solid tumors. III. Gastric cancer. Cancer Treatment Reviews 1: 221-238, 1974.
14. DeVita VT, Wasserman TH, Young RC, et al: Perspectives on research in gynecologic oncology. Cancer 38: 161-177 1976.
15. Skipper HE, Schabel FM, Wilcox WS: Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with "curability" of experimental leukemia. Cancer Chemother Rep 35: 1-111, 1964.
16. Carter SK: The chemical therapy of breast cancer. Semin Oncol 1: 131-144, 1974.
17. Jaffe NJ, Frei E, Traggis D et al: Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. New Engl J Med 201: 994-997, 1974.
18. Cortes EP, Holland JF, Wang J et al: Amputation and adriamycin in primary osteosarcoma. New Engl J Med 291: 998-1000, 1974.